手性金纳米层作为SERS底物用于阿尔茨海默病对映体生物标志物的超灵敏检测，这一成果由江南大学食品科技学院郝昌龙研究团队经过不懈努力而取得。这一研究成果于2025年3月10日发表在国际顶尖学术期刊《德国应用化学》上。

早期诊断神经退行性疾病（如阿尔茨海默病（AD））需要敏感和特异性的生物标志物。

本文成功合成了一种g因子为0.1的D-/ l -半胱氨酸-亮氨酸二肽诱导的新型手性金纳米结构。为了提高识别性能，将手性金纳米结构组装成D-/L-Au单分子层。作为表面增强拉曼散射（SERS）底物，D-/L-Au单层膜在单一光谱内同时具有分子结构特异性和对映体选择性，可以作为一种通用的、无标记的手性鉴别策略来检测D-/ L-犬尿氨酸（Kyn）。该机制揭示了L-和D-Kyn在晶格平面上的高对映选择性吸附能（221），导致对映选择性传感。结果表明，L-Au和D-Au对L-Kyn的检出限分别为3.7nM和3.6nM。值得注意的是，AD患者和健康人血清样本中D-Kyn水平存在显著差异，而L-Kyn未观察到这种差异，这使D-Kyn成为AD患者临床预诊断的潜在新型生物标志物，这是全球首次报道D-Kyn。本研究为生物医学科学和临床诊断提供了一种有效的工具。

附：英文原文

Title: Chiral Gold Nanostructure Monolayers as SERS Substrates for Ultrasensitive Detection of Enantiomer Biomarkers of Alzheimer's Disease

Author: changlong hao, Dan Meng, Wenxiong Shi, Chuanlai Xu, Qing Wang, Hua Kuang

Issue&Volume: 2025-03-10

Abstract: Sensitive and specific biomarkers are needed for early diagnosis of neurodegenerative diseases, such as Alzheimer's disease (AD). Herein, a new type of chiral gold nanostructure induced by D-/L-cysteine-leucine dipeptides with a g-factor of 0.1 was successfully synthesized. To enhance the discrimination performance, the chiral gold nanostructures were assembled into D-/L-Au monolayers. As surface-enhanced Raman scattering (SERS) substrates, the D-/L-Au monolayers simultaneously deliver molecular structural specificity and enantioselectivity within a single spectrum, which can be a versatile, label-free chiral discrimination strategy for the detection of D-/L-kynurenine (Kyn). The mechanism was unveiled to involve high enantioselective adsorption energies between L- and D-Kyn on the lattice plane (221), resulting in enantioselective sensing. The results showed that L-Au monolayer reached a limit of detection (LOD) of 3.7 nM for L-Kyn, while D-Au monolayer reached a LOD of 3.6 nM for D-Kyn, respectively. Notably, there was a significant difference in D-Kyn levels between AD patients and healthy individuals in serum samples, a distinction not observed for L-Kyn, which positioned D-Kyn as a potential novel biomarker for clinical prediagnosis of AD patients, marking the first report of its kind worldwide. This study provides a robust tool for biomedical science and clinical diagnostics.

DOI: 10.1002/anie.202502115

Source: https://onlinelibrary.wiley.com/doi/10.1002/anie.202502115